Integer Holdings Corp (ITGR)
121.24
-0.41
(-0.34%)
USD |
NYSE |
May 31, 16:00
121.23
-0.01
(-0.01%)
After-Hours: 20:00
Integer Holdings Research and Development Expense (Annual): 63.77M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 63.77M |
| December 31, 2022 | 60.92M |
| December 31, 2021 | 51.98M |
| December 31, 2020 | 48.47M |
| December 31, 2019 | 46.53M |
| December 31, 2018 | 48.60M |
| December 31, 2017 | 48.85M |
| December 31, 2016 | 47.90M |
| December 31, 2015 | 53.00M |
| December 31, 2014 | 49.84M |
| December 31, 2013 | 54.08M |
| December 31, 2012 | 52.49M |
| December 31, 2011 | 45.51M |
| Date | Value |
|---|---|
| December 31, 2010 | 45.02M |
| December 31, 2009 | 33.56M |
| December 31, 2008 | 31.44M |
| December 31, 2007 | 29.91M |
| December 31, 2006 | 24.22M |
| December 31, 2005 | 18.72M |
| December 31, 2004 | 18.48M |
| December 31, 2003 | 16.99M |
| December 31, 2002 | 14.44M |
| December 31, 2001 | 12.58M |
| December 31, 2000 | 9.941M |
| December 31, 1999 | 9.339M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
46.53M
Minimum
2019
63.77M
Maximum
2023
54.33M
Average
51.98M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Boston Scientific Corp | 1.414B |
| Abbott Laboratories | 2.741B |
| ResMed Inc | 287.64M |
| Glaukos Corp | 138.77M |
| Perspective Therapeutics Inc | 21.31M |